Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Multiple Myeloma × Aspirin × Clear all

Phase

Status

Completed 4 Terminated 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colonic Neoplasms 3 Adenoma 2 Venous Thromboembolism 1 Urinary Bladder Neoplasms 1 Thrombocytopenia 1 Soft Tissue Neoplasms 1 Rectal Neoplasms 1 Node Positive HER2 Negative Breast Cancer 1 Neoplasms, Plasma Cell 1 Neoplasm Metastasis 1 Myocardial Infarction 1 Multiple Myeloma 1 Hereditary Sensory and Autonomic Neuropathies 1 Hematuria 1 Hematologic Diseases 1 Glioblastoma 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Adenomatous Polyps 1 Adenocarcinoma of Lung 1 Acute Coronary Syndrome 1

Interventions

Dexamethasone 97 Bortezomib 54 Cyclophosphamide 46 Lenalidomide 43 Calcium Dobesilate 39 pomalidomide 28 Melphalan 28 fludarabine 23 Filgrastim 22 carfilzomib 20 fludarabine phosphate 17 daratumumab 17 Whole-Body Irradiation 14 Mycophenolic Acid 14 Granulocyte Colony-Stimulating Factor 14 Antilymphocyte Serum 14 dexamethasone acetate 13 Thalidomide 12 Peripheral Blood Stem Cell Transplantation 12 Cyclosporine 12 Tacrolimus 11 Busulfan 11 dexamethasone 21-phosphate 9 auricularum 9 Radiotherapy 9 pembrolizumab 8 belantamab mafodotin 8 Rituximab 8 Etoposide 8 ixazomib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00790842 2018-10-24

PrE1003

PrECOG, LLC.

Phase 1/2 Terminated

63 enrolled 14 charts

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡